DTMI-Center for Thrombotic and Hemostatic Disorders

杜克转化医学研究所血栓和止血疾病中心(DTMI-CTHD)的总体目标是为杜克大学致力于开发治疗血栓和止血疾病的新方法的研究人员建立一个家，并为他们提供支持。顾名思义，DTMI-CTHD将与CTSA支持的杜克转化医学研究所紧密结合，杜克转化医学研究所是杜克大学所有翻译和临床研究的中心。DTMI-CTHD的科学重点是在急性护理血栓前环境中治疗血栓性疾病。深入的抗血栓治疗在经皮和外科血管重建术中都是至关重要的，以防止由异物和血管损伤引发的凝血和血小板聚集的有害影响。这种有效的抗血栓治疗与出血的常见并发症有关，这使得这种治疗的管理具有挑战性。为了应对这一挑战，我们建立了一个翻译研究计划，该计划有三个研究项目和三个核心。每个项目和核心都由一位经验丰富的调查员(S)领导。项目1将在细胞和动物模型中评估有效的、但解毒剂可控的抗血栓药物组合。项目2将把第一个解毒剂可控抗血小板药物，一种针对von Willebrand因子(VWF)的RNA适配子及其匹配的解毒剂寡核苷酸，转化为1a和1b阶段的研究。项目3将使用临床样本来开发独特的实验室配置文件，这些配置文件可应用于各种临床环境，以预测定向抗血栓治疗的安全性和有效性。这些项目加在一起将产生1.)对普通血管重建术过程中产生的血栓前环境有更全面的基本机制理解，2。将一种控制血小板活性的新方法转化为第一阶段临床试验，以开始解决抗血栓治疗的一个主要挑战，即出血和3。方法确定和管理个体化治疗的最佳抗血栓治疗方法。分子、教育和行政核心将支持每个项目，并促进杜克大学校园内血栓和止血疾病的基础、翻译和临床研究。下面将简要讨论每个项目和核心，以及杜克大学的整体研究环境。

The overall objective of the Duke Translational Medicine Institute Center for Thrombotic and Hemostatic Disorders (DTMI-CTHD) is to establish a home for and provide support for investigators focused upon developing novel approaches to treat thrombotic and hemostatic diseases at Duke University. As its name indicates, the DTMI-CTHD will be tightly integrated with the CTSA supported Duke Translational Medicine Institute, which is the home for all translational and clinical research at Duke. The scientific focus of the DTMI-CTHD is on treating thrombotic disease in acute care prothrombotic settings. Profound antithrombotic therapy is critical during both percutaneous and surgical revascularization procedures to prevent deleterious effects of coagulation and platelet aggregation triggered by foreign materials and vascular trauma. Such potent antithrombotic therapy is associated with the common complication of bleeding which makes management of such therapy challenging. To address this challenge, we have established a translational research program that has three research projects and three cores. Each project and core is led by a seasoned investigator(s). Project 1 will evaluate potent, yet antidote controllable combinations of antithrombotic agents in cell and animal based models. Project 2 will translate the first antidote controllable antiplatelet agent, a RNA aptamer against von Willebrand factor (VWF) and its matched antidote oligonucleotide, into phase 1a and 1b studies. Project 3 will employ clinical samples to develop unique laboratory profiles that can be applied to various clinical settings to predict the safety and efficacy of targeted antithrombotic therapy. Collectively these projects will result in 1.) a more thorough basic mechanistic understanding of the prothrombotic environment engendered during common revascularization procedures, 2.) translation of a novel approach to control platelet activity into a phase 1 clinical trial to begin to address a major challenge of antithrombotic therapy, bleeding and 3.) methods to identify and manage the optimal antithrombotic therapy for treatment of individual patients. The molecular, educational and administrative cores will support each of these projects as well as facilitate basic, translational and clinical research on thrombotic and hemostatic disorders across the Duke campus. Each project and core will be briefly discussed below along with the overall research environment at Duke.